Compare Organon & Co. Common Stock (OGN) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Royal Bank of Canada — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Royal Bank of Canada trades at $193.5 (market cap $268.76B). The key difference: Royal Bank of Canada is far larger — about 74.2× Organon & Co. Common Stock's market cap, and Royal Bank of Canada pays the higher dividend (2.61%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Royal Bank of Canada for 48 Days on average.
| OGN | RY | |
|---|---|---|
Market Cap | $3.62B | $268.76B |
Volume | 2,892,999 | 1,509,016 |
Sector | Health | Financials |
52-Week High | $13.81 | $217.87 |
52-Week Low | $5.70 | $145.31 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $11.04B | $738.98B |
Dividend Yield | 0.58% | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Royal Bank of Canada (RY) trades at $193.82, up 0.55% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations. Revenue growth accelerated to $66.53B in 2025 with net income margin improving to 32.01%. Analyst consensus leans neutral with 43% buy ratings while technical indicators show resistance near $194.
RY presents a mixed outlook with robust profitability and dividend stability offset by stretched valuations and bearish technicals. The bank's 18% ROE and U.S. expansion provide upside potential, though high P/E of 17.5 and negative cash flow trends warrant caution. Near-term performance hinges on Q3 earnings due October 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
